IPP Bureau
FDA approves first immunotherapy for recurrent respiratory papillomatosis
By IPP Bureau - August 19, 2025
Tonix receives FDA approval of Tonmya for treatment of fibromyalgia
By IPP Bureau - August 19, 2025
Sarepta advances siRNA collaboration and sale of arrowhead equity investment
By IPP Bureau - August 19, 2025
Sarepta has also entered into an agreement with Arrowhead to transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the company’s previously announced $100 million milestone payment obligation
BioAge Labs doses first patient in BGE-102 phase 1 trial
By IPP Bureau - August 19, 2025
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Pfizer’s sickle cell disease candidate fails Phase III trial
By IPP Bureau - August 19, 2025
Inclacumab was generally well tolerated in THRIVE-131
Shanmuga Hospital commissions advanced PH impedance and manometry system
By IPP Bureau - August 18, 2025
This system enables comprehensive diagnosis of both acid and non-acid reflux, along with esophageal motility disorders.
Kwality Pharma receives product registration of Bleomycin 15 IU per vial in Mexico
By IPP Bureau - August 18, 2025
The projected business potential is around US$ 1 million in the first year
Merck and mantro launch EdiMembre to transform alternative protein industry
By IPP Bureau - August 18, 2025
Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
FDA grants breakthrough therapy designation to Ifinatamab Deruxtecan for lung cancer patients
By IPP Bureau - August 18, 2025
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
European Commission grants approval of Ogsiveo
By IPP Bureau - August 18, 2025
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Xspray Pharma licenses patent rights to Handa Therapeutics, secures royalty agreement
By IPP Bureau - August 17, 2025
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
AN2 Therapeutics begins first-in-human trial of oral AN2-502998 for chagas disease
By IPP Bureau - August 17, 2025
Phase 1 dosing is expected to finish by the end of 2025
STEER World achieves 200 kg/hr continuous granulation with patented INTEGRAAL system
By IPP Bureau - August 17, 2025
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
Alkem reports posts Q1 FY26 net profit 22% higher at 664.3 Cr
By IPP Bureau - August 17, 2025
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
